RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-x
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fs2352-3026%2824%2900139-x
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
prism:doi |
10.1016/s2352-3026(24)00139-x |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
dcterms:title |
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
rdf:type |
node1 |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |
owl:sameAs |
https://semopenalex.org/work/W4399672192 |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs2352-3026%2824%2900139-xEfficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study |